In Brief ASXL2 regulates glucose homeostasis, adipogenesis, and osteoclast differentiation by activating PPARg. Izawa et al. find that ASXL2-deficient mice are insulin resistant, lipodystrophic, and osteopetrotic. ASXL2 promotes osteoclast formation in a Fos-dependent manner independent of PGC-1b. ASXL2 enhances osteoclast mitochondrial biogenesis in a process mediated by PGC-1b but independent of c-Fos.
INTRODUCTION
The incidence of insulin-resistant diabetes mellitus is probably the most rapidly increasing of any endemic disease in the United States. Obesity promotes type 2 diabetes (T2-DM), but not all obese individuals have diabetes, suggesting that the influence of genetic factors, particularly in specific ethnic groups, is substantial. T2-DM has skeletal complications. Diabetic patients are predisposed to fractures that heal poorly, in part because of compromised osteoclast function (de Liefde et al., 2005; Hernandez et al., 2012; Janghorbani et al., 2007; Kasahara et al., 2010; Vestergaard, 2007) . Osteoclasts also probably contribute to the increased fracture incidence reported with thiazolidinedione (TZD) therapy (Kasahara et al., 2010; Lazarenko et al., 2007; Li et al., 2006; Sottile et al., 2004; Wan et al., 2007) . Furthermore, recent evidence indicates the skeleton promotes glucose homeostasis via the osteoblast-specific protein, osteocalcin (Lee et al., 2007) . The osteoclast is proposed to participate in this process by de-carboxylating osteocalcin and thus enabling it to stimulate pancreatic b cells to produce insulin (Ferron et al., 2010) .
We recently utilized genome-wide screening to identify bone mineral density (BMD)-associated genes in mice (Farber et al., 2011) and found that the most-significant BMD SNPs were in the ASXL2 gene. Establishing clinical relevance, SNPs within ASXL2 are associated with human BMD in two cohorts (Ghazalpour et al., 2012; Nielson et al., 2010) .
ASXL2 is a mammalian homolog of the Drosophila gene, ASX, which encodes an ETP protein, regulating histone methylation (Baskind et al., 2009) . To gain insight into the means by which ASXL2 impacts the skeleton, we performed gene cluster analysis (Farber et al., 2011 ). Because we found the genes most prominently co-expressed with ASXL2 are those mediating myeloid differentiation, we postulated ASXL2 likely impacts the osteoclast, a member of the monocyte/macrophage family. In the present study, we find ASXL2À/À osteoclastogenesis is attenuated in vitro and in vivo. In keeping with a paucity of bone-resorptive cells, trabecular bone mass is increased more than 400% in mice lacking ASXL2.
PPARg is a nuclear receptor that, in its unliganded state, is inactive due to association with co-repressing molecules (Tontonoz and Spiegelman, 2008) . Upon ligand-induced activation, corepressors disassociate and PPARg recruits co-factors that enable transactivation of target genes. This nuclear receptor regulates insulin sensitivity and adipogenesis and can be involved in the pathogenesis of T2-DM. The preponderance of evidence indicates that fat is the primary tissue targeted by PPARg to enhance insulin sensitivity where it promotes storage of dietary fatty acids in adipose tissues. TZDs, pharmacological activators of PPARg, exert their insulin-sensitizing effects primarily by lowering free fatty acids.
TZDs, such as rosiglitazone (ROSI) have, until recently, enjoyed wide use in treating insulin resistance. Administration of these drugs is, however, restricted because of complications, including predisposition to fracture (Grey, 2009) . Thus, the means by which activated PPARg compromises the skeleton has important clinical implications.
PPARg exerts its skeletal effects by impacting both osteoblasts and osteoclasts. In the case of osteoblasts, the nuclear receptor commits common precursor mesenchymal stem cells to differentiate into adipocytes at the cost of osteoblastogenesis, thereby reducing bone formation. PPARg promotes osteoclast differentiation via activation of the osteoclastogenic AP-1 transcription factor, c-Fos (Wan et al., 2007) . Thus, a reasonable hypothesis holds that TZD-mediated bone loss represents suppressed formation and enhanced resorption. In fact, enhanced resorption is the exclusive cause of ROSI-induced bone loss in mice (Fukunaga et al., 2015) and a component of the increased fracture risk in women (Zinman et al., 2010) .
ASXL2 interacts with PPARg and activates adipogenic genes (Park et al., 2011) , raising the possibility ASXL2 may participate in the bone-regulating effects of the nuclear receptor. We find that ASXL2 is necessary for cell-autonomous osteoclastogenesis in a PPARg/c-Fos-dependent manner. Thus, ASXL2 deficiency obviates the osteoclast-inducing capacity of ROSI. ASXL2 also promotes mitochondrial biogenesis in osteoclasts via PGC1-b in a manner independent of differentiation and c-Fos expression. Attesting to its cell specificity, ASXL2 does not regulate osteoblastic bone formation. Furthermore, ASXL2-deficient mice are lipodystrophic and relatively unresponsive to high-fat diet (HFD). They have impaired glucose homeostasis, and liver, fat, muscle, and osteoclast precursors are insulin resistant. Thus, ASXL2 regulates skeletal, glucose, and adipocyte homeostasis.
RESULTS

ASXL2 Deficiency Inhibits Osteoclastogenesis
With the discovery that ASXL2 SNPs are associated with murine BMD, we knocked ASXL2 down in osteoclast precursors in the form of bone marrow macrophages (BMMs) and discovered a marked arrest of osteoclastogenesis (Farber et al., 2011) . To determine the physiological relevance of this observation, we cultured BMMs of ASXL2À/À mice in M-CSF and increasing amounts of the osteoclast-differentiating cytokine, RANK ligand (RANKL). ASXL2-deficient osteoclast number is substantially reduced at all RANKL concentrations ( Figures 1A and S1A ). Similarly, temporal expression of osteoclast differentiation markers is arrested in RANKL + M-CSF-exposed ASXL2À/À BMMs ( Figures 1B and S1B ). Reflecting reduced numbers of the bone-resorptive cells, mobilization of CTx, a product of collagen degradation, is diminished in cultures of ASXL2À/À osteoclasts generated on bone ( Figure 1C ). Osteoclastogenesis of ASXL2+/À BMMs mirrors WT (not shown).
The fact that osteoclastogenesis of ASXL2À/À BMMs is dampened, in the absence of stromal cells or osteoblasts, suggests the influence of a mechanism endogenous to the osteoclast precursor (osteoclast autonomous). To determine whether such is the case, we transduced ASXL2À/À BMMs with ASXL2 or empty vector. Likely because of construct size, transduction efficiency is less than optimal, resulting in ASXL2 expression approximately 1/3 that of WT cells ( Figure S1C ). Despite this limitation, ASXL2 substantially, although incompletely, rescues osteoclast formation by mutant BMMs, establishing a cellautonomous influence ( Figure 1D ). In keeping with the partial rescue of the mutant cells by the WT construct, expression of the osteoclastogenic transcription factors, c-Fos and NFATc1 are significantly but modestly increased ( Figure S1C ). Because the partial rescue of ASXL2À/À osteoclastogenesis by ASXL2 transduction raised the possibility of a non-cell-autonomous influence, we generated various co-cultures of mutant and WT BMMs and osteoblasts in osteoclastogenic conditions. These experiments were based upon the fact that cytokines produced by osteoblast lineage cells are the key inducers of osteoclast differentiation. Consistent with diminished RANKL expression ( Figure S1D ), ASXL2À/À osteoblasts exert a modest negative influence on commitment of WT BMMs to the osteoclast phenotype ( Figure 1E ). Osteoclastogenesis, however, is virtually arrested when mutant BMMs are cultured with either WT or ASXL2-deficient osteoblasts. Thus, whereas RANKL production by ASXL2À/À osteoblast lineage cells is dampened, the deficiency does not contribute to the diminished number of mutant osteoclasts.
Exposure of BMMs to mesenchymal cell-produced RANKL, in vivo, primes them to differentiate into osteoclasts, ex vivo (Lam et al., 2000) . To determine whether ASXL2À/À osteoclast precursors respond to such priming, we transplanted WT or ASXL2À/À marrow in irradiated WT mice, a model in which all derivative osteoclasts, but not osteoblasts, are of donor origin (Lam et al., 2000) . Marrow was obtained from the transplanted animals after 6 weeks and BMMs cultured in RANKL + M-CSF. BMMs of WT > WT chimeras generate abundant osteoclasts, which are virtually absent when the cultured cells are obtained from marrow of ASXL2À/À > WT chimeras ( Figure 1F ). Thus, in keeping with the cell-autonomous nature of the process, ASXL2À/À osteoclast precursors are resistant to priming by differentiation-inducing cytokines, in vivo.
ASXL2À/À Mice Are Osteopetrotic
These observations establish that ASXL2 deficiency compromises osteoclast formation in a cell-autonomous manner. Because osteopetrosis represents increased bone mass due to compromised osteoclast formation and/or function, we measured bone mass of mutant mice by mCT. In fact, femoral trabecular bone mass (BV/TV) is increased approximately 400% in ASXL2À/À mice ( Figure 1G ). Trabecular connectivity, spacing, and number exhibit equally impressive changes (Figure S1E ). Histomorphometric analysis reveals the same abundance of trabecular bone mass, and in keeping with our in vitro data, a significant decrease in osteoclast number ( Figure 1H ). Interestingly, whereas vertebral BV/TV is increased in absence of ASXL2, the change is relatively modest compared to appendicular bone ( Figure S1F ). Similar to other osteopetrotic animals, cortical thickness is reduced, eventuating in compromised bone strength ( Figure S1G ) (Li et al., 1999) . As in human glucose intolerance (vide infra), fracture healing of ASXL2À/À mice is also retarded ( Figure S1H ).
Osteopetrosis is often associated with splenomegaly due to extramedullary hematopoiesis, and ASXL2À/À mice have enlarged spleens (p < 0.01). An abundance of megakaryocytes (not shown), taken with a paucity of bone marrow cells, establishes the splenomegaly of the mutant mice reflects extramedullary hematopoiesis ( Figure S1I ).
These data stand in contradistinction to our report of decreased BMD, as determined by DXA, in ASXL2À/À mice (Farber et al., 2011) . DXA analysis is, however, modified by subject size, and the results decrease in face of smaller bone, thus obviating meaningful interpretation in pediatric patients (Reid, 2010) . In this regard, ASXL2À/À mice are smaller and weigh less than their WT counterparts ( Figure 1I ). The fact that the projected bone area of ASXL2À/À femurs is reduced approximately 1/3 (WT 0.96 ± 0.03 mm 2 ; ASXL2À/À 0.67 ± 0.03 mm 2 ; p < 0.01) explains the discrepancy between the substantially enhanced trabecular bone volume determined by mCT and the artifactually low BMD measured by DXA. ASXL2 is abundantly expressed in osteoblasts (Farber et al., 2011) . Thus, whereas our data establish ASXL2À/À mice are osteopetrotic, it is possible that, as in other forms of osteopetrosis, enhanced osteoblast activity may contribute to the increased bone mass (Marzia et al., 2000) . ASXL2, however, does not appear to regulate bone formation because temporal expression of osteocalcin, bone sialoprotein, alkaline phosphatase, and collagen 1 mRNA, by ASXL2À/À and WT cultured osteoblasts, is indistinguishable ( Figure S1J ). The same holds regarding in vivo osteoblast number and circulating osteocalcin ( Figures 1H and S1K ). Moreover, differentiation of marrow stromal cells into bone-forming osteoblasts is unaltered in absence of ASXL2 ( Figure S1L ). To kinetically determine the impact of ASXL2 deletion on osteogenesis, we administered time-spaced doses of calcein and measured parameters of bone formation in non-decalcified sections. Mineral apposition (MAR) and bone formation (BFR) rates are the same in ASXL2À/À and WT animals ( Figure 1H ). Thus, ASXL2 deficiency increases bone mass by attenuating osteoclast formation without impacting osteoblasts.
PPARg Mediates ASXL2-Stimulated Osteoclastogenesis Activated PPARg promotes osteoclastogenesis, and its absence, in BMMs, inhibits differentiation into mature boneresorbing cells (Wan et al., 2007) . Furthermore, conditional deletion of the nuclear receptor in hematopoietic and endothelial cells increases bone mass (Wan et al., 2007) . ASXL2 and PPARg interact in other cells, raising the possibility the nuclear receptor may mediate ASXL2's osteoclastogenic capacity (Park et al., 2011) . To test this hypothesis, we first asked whether the ASXM2 domain of ASXL2, which is the binding site of PPARg's transcriptional partner, RXRa (Katoh, 2013) , mediates osteoclast formation. In contrast to the induction of osteoclast differentiation markers by WT ASXL2, lacking the ASXM2 domain is incapable of doing so in mutant BMMs ( Figure S2A ; relative mRNA expression: Vect = 1; WT = 1.9; Delta ASXM2 = 2.4).
We next transfected 293T cells with a PPARg luciferase reporter, with or without PPARg ( Figure 2A ). Co-transfection with ASXL2 dose dependently increases luciferase activity only in the presence of PPARg (Figure 2A ). Furthermore, ROSI, which therapeutically stimulates PPARg in diabetic patients, synergistically enhances the capacity of ASXL2 to induce the PPARg reporter construct. ROSI also substantially increases ASXL2/ PPARg association ( Figure 2B ). Further supporting its regulation of the nuclear receptor's osteoclastogenic effects, induction of the PPARg target gene, CD36, requires ASXL2 ( Figure 2C ). ASXL2 also dampens PPARg SUMOylation, a process which represses the nuclear receptor's transcriptional activity (van Beekum et al., 2009) (Figure 2D ). Establishing a central role of ASXL2 in PPARg-mediated osteoclast formation, induction of the bone-resorptive polykaryon, by ROSI, is completely arrested in knockout cells (Figures 2E and S2B) . On the other hand, ROSIinduced osteoclastogenesis does not reflect stimulated expression of ASXL2 by the TZD ( Figure S2C ) nor does ASXL2 deficiency affect PPARg expression ( Figure S2D ). Thus, ASXL2 partners with ROSI to promote osteoclast formation via PPARg activation.
c-Fos Mediates ASXL2-Induced Osteoclastogenesis ASXL2 is essential for RANKL-stimulated expression of the AP-1 transcription factor, c-Fos, deficiency of which completely arrests osteoclastogenesis, thereby promoting severe osteopetrosis (Figures 2F and S2E) (Grigoriadis et al., 1994) . In keeping with c-Fos's essential role as an ASXL2 effector, transduction of the AP-1 protein rescues the osteoclastogenic capacity of ASXL2À/À BMMs ( Figures 2G, 2H , S2F, and S2G). Interestingly, c-Fos is a PPARg target gene whose expression is enhanced in osteoclast precursors by ROSI (Wan et al., 2007) . In fact, in the absence of ASXL2, PPARg binding to its c-Fos response element does not increase with osteoclast differentiation, nor is it heightened by ROSI ( Figure 2I ).
RANK-Stimulated Osteoclast Formation Requires ASXL2
Differentiation of progenitors into mature osteoclasts is principally, if not exclusively, the purview of RANKL. In this regard, transduction of the RANKL-induced, essential transcription factor, NFATc1 substantially rescues the osteoclastogenic capacity of ASXL2À/À BMMs ( Figures 3A-3C ). Consistent with c-Fos being upstream of NFATc1 in osteoclastogenesis, transduction of NFATc1 does not increase c-Fos expression in ASXL2À/À osteoclasts ( Figure 3D) . It therefore appears that the impaired osteoclastogenesis of ASXL2À/À BMMs reflects failed activation of the RANKL canonical signaling pathway. In fact, RANKL-stimulated cytoplasmic and nuclear osteoclastogenic signals are compromised in ASXL2À/À cells ( Figures 3E and  3F) . Furthermore, RANK expression by BMMs and pre-fusion osteoclasts is diminished in the absence of ASXL2 ( Figure 3G ).
These observations suggest that normal expression of RANK, when activated, is necessary and may be sufficient to mediate ASXL2-stimulated osteoclast formation. Such being the case, activated RANK should rescue the ASXL2À/À osteoclast phenotype. To confirm this notion, we expressed a protein consisting of the transmembrane and cytosolic domains of RANK fused to the external domain of human Fas receptor (hFas/RANK) (Izawa et al., 2012) . When exposed to anti-hFas antibody, WT macrophages bearing this construct differentiate into osteoclasts ( Figure 3H ). ASXL2À/À BMMs, however, fail to do so. This observation is in keeping with the failure of RANKL abundance to influence differentiation of ASXL2À/À osteoclast precursors ( Figures 1E and S1D) . Thus, even in the presence of activated RANK, ASXL2 is necessary for the osteoclastogenic process.
c-Fos expression is central to the means by which activated RANK promotes osteoclast formation. Because ASXL2 is also required for c-Fos expression, we asked whether the inability of hFas/RANK to rescue the mutant cells reflects failure to induce the AP-1 transcription factor, and we find such to be the case ( Figure 3I ). Thus, the osteoclastogenic properties of RANK require ASXL2, which is essential for expression of the RANKL receptor, as well as c-Fos.
ASXL2 Promotes PGC-1b Expression and Osteoclastogenic Activity
Like PPARg, its co-activator, PGC-1b, is essential for osteoclastogenesis, in vitro (Ishii et al., 2009) . Given the functional relationship between PPARg and PGC-1b, we asked whether the latter participates in ASXL2's osteoclastogenic properties. Unlike the stable expression of ASXL2 ( Figure S2C ), PGC-1b progressively increases during osteoclastogenesis in an ASXL2-dependent manner ( Figures 4A and 4B ). In fact, absence of ASXL2 obviates both basal and ROSI-stimulated PGC-1b expression during osteoclast differentiation (Figures 4A-4C) . Furthermore, ASXL2 localizes with PGC-1b on the retinoic acid response element, a process mediated by PPARg activation as evidenced by the stimulatory effect of ROSI ( Figure 4D ).
PGC-1b is proposed to impact the osteoclast by two distinct yet integrated pathways. First, by activating PPARg, PGC-1b is believed to participate in c-Fos induction . Second, PGC-1b, when reciprocally induced by activated PPARg, promotes mitochondrial biogenesis, considered necessary for osteoclast differentiation and/or function (Ishii et al., 2009; Wei et al., 2010) . To determine whether ASXL2 regulates generation of osteoclast mitochondria, we treated mutant and WT BMMs with various combinations of RANKL ± ROSI. Mitochondrial enzyme mRNA abundance was determined after 3 days. Consistent with the copious mitochondria characterizing mature osteoclasts, basal-and ROSI-induced enzyme mRNA expression is blunted in cells lacking ASXL2 ( Figure 4E ). Thus, ASXL2 is necessary for normal mitochondrial biogenesis, which is augmented by activated PPARg.
Given its central role in osteoclast mitochondrial biogenesis, we next asked whether PGC-1b mediates ASXL2's effects on the process. Thus, we transduced ASXL2À/À BMMs with PGC-1b and exposed them to M-CSF ± RANKL. PGC-1b completely normalizes mitochondrial enzyme expression by ASXL2À/À osteoclast lineage cells ( Figure 4F) . Surprisingly, however, PGC-1b does not rescue the failure of ASXL2-deficient BMMs to commit to the osteoclast phenotype and is actually suppressive, as evidenced by decreased cathepsin K ( Figure 4G ). This observation raised the possibility that PGC-1b does not induce essential osteoclastogenic transcription factors such as c-Fos. To determine whether this is so, we transduced ASXL2À/À BMMs with c-Fos or PGC-1b. Vectorbearing ASXL2À/À cells served as control. The cells were cultured for 24 hr in M-CSF, with or without RANKL. Despite robust expression of transduced c-Fos and PGC-1b, each fails to enhance mRNA of the other in ASXL2À/À BMMs or prefusion osteoclasts (pOCs) ( Figure 4H ). In fact, PGC-1b actually diminishes c-Fos mRNA abundance. Furthermore, whereas PGC-1b rescues expression of the five principal eukaryotic mitochondrial enzyme complexes (OXPHOS proteins) in ASXL2À/À BMMs and/or pOCs, c-Fos has no such effect (Figure 4I) . Hence, PGC-1b and mitochondrial biogenesis, together, are insufficient to promote ASXL2À/À osteoclast formation as they do not induce c-Fos or the osteoclast-specific protein, cathepsin K. Similarly, c-Fos fails to induce PGC-1b expression or mitochondrial biogenesis. These observations suggest ASXL2 regulates two distinct pathways in osteoclasts. The first involves PGC-1b-stimulated energy metabolism, which mediates the mature cell's capacity to degrade bone, whereas the second involves c-Fos promotion of osteoclast differentiation.
ASXL2 Does Not Suppress Key PPARg Co-repressors
These data indicate ASXL2 likely promotes osteoclastogenesis in association with transactivation of PGC-1b, a PPARg co-activator. However, they do not exclude the possibility that ASXL2 also exerts its osteoclastogenic effects by suppressing transcription of a PPARg co-repressor(s). This hypothesis is in keeping with the fact that ASXL2 is an ETP protein that regulates histone 3 methylation to establish repressive or active chromatin configurations at target loci (Baskind et al., 2009 ). Indicating ASXL2 does not suppress PPARg co-repressors, the mRNA abundance of two such key inhibitors, NCoR and SMRT, does not increase in the absence of the ETP protein (Yu et al., 2005) (Figure S3 ). Thus, the osteoclastogenic properties of ASXL2 are mediated by activating PPARg and probably not by inhibiting its repression.
ASXL2 Deficiency Promotes Insulin Resistance and Glucose Intolerance
PPARg plays a central role in insulin sensitivity. Because ASXL2 activates PPARg in the osteoclastogenic process, we postulated ASXL2 may also promote glucose homeostasis. In fact, ASXL2À/À mice are glucose intolerant ( Figure 5A ). Consistent with this condition, basal serum glucose is increased in fasting and fed states (Fast-WT 65.4 ± 11.4; ASXL2À/À 112.6 ± 18.4; Fed-WT 118.7 ± 15.26; ASXL2À/À 170.75 ± 31.82; mg/dl ± SD; p < 0.01). On the other hand and typical of early onset T2-DM, their circulating basal insulin is normal (WT 0.31 ± 0.10; ASXL2À/À 0.32 ± 0.17; ng/ml ± SD). Asxl2-deficient mice also exhibit attenuated clearance of glucose following insulin challenge ( Figure 5B ). Insulin resistance in ASXL2-deficient mice is further substantiated by the inability of liver and muscle to phosphorylate Akt or the insulin receptor in response to in vivo insulin administration ( Figures  5C and 5D ). The mice also exhibit increased hepatic expression of the gluconeogenic enzymes, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase ( Figure 5E ). The role of PPARg in ASXL2À/À extraskeletal insulin resistance is supported by suppressed expression of CD36 in mutant liver, fat, and muscle ( Figure 5F ) (Hu et al., 2012) . Thus, ASXL2 deficiency produces a state of insulin-resistant glucose intolerance in conjunction with failed osteoclastogenesis and osteopetrosis.
ASXL2 Does Not Regulate Glucose Metabolism via Its Expression in Osteoclasts
Osteoclasts may participate in the pathogenesis of murine diabetes (Ferron et al., 2010) . To determine whether ASXL2 deficiency in the bone-resorptive cell modifies glucose homeostasis, we transplanted WT or ASXL2À/À marrow into irradiated WT mice (Lam et al., 2000) . Despite the fact that transplantation of the mutant marrow into irradiated WT mice yields the ASXL2À/À osteoclast phenotype ( Figure 1F ), glucose tolerance remains normal as it mirrors that of WT to WT transplantation ( Figure 5G ). Thus, in contrast to murine T1-DM, in which osteoclast dysfunction might be pathogenic (Ferron et al., 2010) , the resorptive cell's abnormalities do not appear to contribute to systemic insulin resistance in ASXL2 deficiency.
ASXL2-Mediated Insulin Sensitivity Does Not Regulate
Osteoclastogenesis ASXL2À/À BMMs are also insulin resistant, as evidenced by diminished InR, Akt, and S6(S235/236) phosphorylation in response to the hormone (Figures 5H-5J ). As BMMs are osteoclast precursors, this observation suggests their insulin insensitivity may contribute to the attenuated osteoclastogenesis attending ASXL2 deficiency. To determine whether insulin signaling in osteoclast precursors is necessary for the osteoclastogenic process, we deleted the InR in InR fl/fl BMMs, with retroviral Turbo-cre (Bai et al., 2008) . As seen in Figures S4A and S4B , absence of the InR does not alter differentiation of osteoclast precursors. Thus, failure of ASXL2-deficient osteoclast formation does not reflect insulin insensitivity of precursors.
ASXL2À/À Mice Are Lipodystrophic
PPARg is required for adipogenesis, and its absence produces a lipodystrophic state. Similarly, ASXL2 overexpression in 3T3-L1 pre-adipocytes transactivates adipogenic genes (Park et al., 2011) . In consequence, ASXL2À/À mice are partially lipodystrophic, as manifested by decreased abundance of epididymal (eWAT) and subcutaneous (scWAT) white and brown (BAT) adipose tissue as well as DXA-determined fat/lean ratio ( Figures  6A, 6B , S5A, and S5B). Despite the paucity of fat, VO 2 is only slightly decreased and exclusively in light cycle ( Figure S5C ). Likewise, respiratory quotient (RQ) of ASXL2À/À mice mirrors that of WT. These data suggest ASXL2À/À and WT mice enjoy similar use of fuels as energy source. ASXL2À/À adipocytes are insulin insensitive, as they fail to optimally phosphorylate Akt 308 in response to the hormone (Figure 6C) . Mirroring cells in which PPARg is inactive, ASXL2-deficient adipocytes are small and their abundance is diminished ( Figures 6D, 6E , S5D, and S5E). Histological analysis of BAT and expression of the thermogenic marker, UCP1, remains unchanged in eWAT and BAT, suggesting beiging of WAT does not induce the small adipocytes of ASXL2 deficiency ( Figures S5F and  S5G ). Unlike cells in muscle and liver, ASXL2À/À adipocytes normally phosphorylate their InR ( Figure S5H ). On the other hand, expression of adiponectin and leptin by adipocyte is reduced, attesting to insulin insensitivity and the lipodystrophic phenotype ( Figure 6F ). Confirming compromised adipogenic capacity, differentiation of ASXL2À/À marrow stromal cells into fat is arrested ( Figure 6G ). Similarly, shRNA knockdown of ASXL2 reduces lipid accumulation in NIH 3T3-L1 cells, corroborating the cell-autonomous nature of the process ( Figure S5I) . Additionally, C/EBPa mRNA, whose product regulates leptin and PPARg expression and promotes osteoclast formation (Chen et al., 2013) , is reduced in ASXL2À/À fat ( Figure 6F ). The same holds regarding mRNA for AP2, CD36 (both induced by PPARg), and solute carrier family 25, member 1 (slc25a1). In contrast to these proteins, which promote maturation of differentiating adipocytes, expression of C/EBPb, which stimulates earlier, pre-adipocyte maturation, is increased.
ASXL2 deletion does not affect glycerol mobilization even in presence of isoproterenol induction, indicating that the attendant paucity of fat is not due to enhanced lipolysis ( Figure 6H ). On the other hand, proteins, which mediate lipid storage, including fatty acid synthase (Fasn), acetyl-CoA carboxylase 1 (Acaca), malic enzyme 1 (Me1), and Glut 4, are diminished in ASXL2À/À WAT ( Figure 6I ). In keeping with failure to store lipids, circulating triglycerides and cholesterol are increased in ASXL2-deficient mice ( Figure 6J ). Despite compromised lipid storage, liver and muscle fat are not enhanced in the mutant mice ( Figures S5J-S5L) . Thus, the lipodystrophic state of ASXL2À/À mice likely reflects defective lipid storage and not enhanced lipolysis.
ASXL2-Deficient Mice Resist HFD
Obesity promotes insulin resistance, suggesting that compromised adipogenesis may be protective in this regard. To determine whether such is the case, we fed WT and ASXL2À/À mice a HFD for 7 weeks. As expected WT mice gain substantial weight. In contrast, ASXL2-deficient animals fail to increase body mass despite similar food consumption ( Figures 7A and  7B) . Hence, the fat/lean ratio, as determined by DXA, remains low in HFD-fed ASXL2À/À mice ( Figure 7C ). Whereas there is no discernable difference in marrow adipose tissue in chowfed animals, there is substantially less in the pair of femurs obtained from ASXL2À/À HFD mice (Table S1) .
As expected, the metabolic phenotype is exacerbated in WT animals by HFD (Figures 7D-7F ). Chow-fed ASXL2À/À mice are insulin resistant based on glucoseand insulin-tolerance tests, but this condition is not exacerbated by HFD. Lipokine levels reflect the expected physiology in WT mice with increases in leptin and decreases in adiponectin ( Figure 7F ), but these changes are substantially blunted in ASXL2À/À mice. This robust difference is consistent with the complex lipodystrophic phenotype of these mice and highlights the critical role of ASXL2 in the integrative physiology of lipid, glucose, and skeletal metabolism.
DISCUSSION
Our exploration of ASXL2 was prompted by its association with BMD in mice and man (Farber et al., 2011; Ghazalpour et al., 2012; Nielson et al., 2010) . Because ASXL2 expression is linked to genes regulating myeloid differentiation, we suspected its skeletal effects are mediated via the osteoclast. In fact, both knockdown of ASXL2 and its absence in osteoclast precursors markedly arrest the osteoclastogenic process. Mirroring these in vitro experiments, the number of osteoclasts in ASXL2À/À mice is substantially reduced and ASXL2À/À mice are osteopetrotic. These animals also manifest systemic insulin resistance. These observations suggest that ASXL2 may participate in the complex relationship between skeletal biology and metabolism manifest in obesity-related diabetes.
Osteoclast formation may be regulated in a cell-autonomous (i.e., endogenous to the osteoclast) or non-autonomous manner. Non-autonomous osteoclastogenesis typically involves altered secretion of the key osteoclastogenic cytokines, RANKL and M-CSF, by non-osteoclastic cells such as those of mesenchymal or T cell lineage. Despite compromised RANKL expression by mutant osteoblasts, our observation that pure populations of ASXL2À/À BMMs fail to normally differentiate into osteoclasts indicated ASXL2's effects are principally cell autonomous. On the other hand, the magnitude of priming BMMs by RANKL, in vivo, may affect their subsequent capacity to commit to the osteoclast phenotype (Lam et al., 2000) . The fact that the WT construct substantially rescues ASXL2À/À osteoclastogenesis that, in turn, is induced by transplantation of mutant marrow into irradiated WT mice substantiates ASXL2's osteoclast autonomous nature.
Our conjecture that the osteoclastogenic effects of PPARg require ASXL2 was prompted by the observation that the two nuclear proteins interact (Park et al., 2011) . The essential role ASXL2 plays in PPARg-induced osteoclast formation is established by ASXL2 being necessary for basal and TZD-stimulated activation of a PPARg reporter construct. ASXL2 also promotes binding of PPARg to its c-Fos response element and, most importantly, is essential for expression of c-Fos and NFATc1. These observations indicate that the attenuated osteoclastogenesis attending ASXL2 deficiency reflects failure to express these TZD-induced transcription factors. Establishing this case, transduction of c-Fos or NFATc1 in ASXL2À/À BMMs promotes their differentiation into osteoclasts.
Osteoblasts and adipocytes have a common mesenchymal precursor, and therefore, their differentiation is competitive (Wan, 2010) . PPARg plays a central role in this selection as its activation promotes adipogenesis at the cost of the osteoblast. Based on the abundance of ASXL2 in osteoblasts, we expected its deficiency would enhance bone formation, contributing to the marked increase in trabecular bone volume. By this scenario, ASXL2 deficiency would obviate the pro-adipogenic effects of PPARg, thereby encouraging osteoblast differentiation of their common precursor. Our in vitro and in vivo data establish such is not the case, as multiple parameters of bone formation, including osteocalcin, are unaltered in ASXL2À/À mice. Interestingly, the metabolic characteristics of ASXL2À/À mice, which have normal circulating osteocalcin and insulin, differ from those deficient in the osteoblast-specific protein. For example, lack of osteocalcin promotes obesity (Lee et al., 2007) . In contrast, fat mass and adipocyte differentiation of ASXL2À/À mice are diminished, likely reflecting relatively late arrest of the adipogenic process and lipid storage. Thus, regulation of glucose homeostasis by osteocalcin and ASXL2 mechanistically differ. Whereas decreased osteocalcin principally compromises insulin production, absence of ASXL2 results in insulin resistance. Furthermore, despite evidence indicating the osteoclast participates in osteocalcin-mediated glucose homeostasis (Ferron et al., 2010) , WT marrow transplanted into ASXL2À/À mice fails to rescue their diabetic state. Thus, whereas bone and glucose metabolism are each mediated by PPARg, the effects of ASXL2 on the two events appear to be physiologically distinct. Our demonstration that, unlike ROSI, a TZD with impaired recognition of PPARg (Chen et al., 2012) fails to promote osteoclast formation provides credence to the concept that insulin sensitivity of BMMs does not impact their osteoclastogenic potential (Fukunaga et al., 2015) .
The activity of PPARg is dictated by ligand-induced disassociation of co-repressors and recruitment of co-stimulatory molecules. The varied distribution of PPARg co-activators likely dictates tissue specificity of the nuclear receptor's transcriptional effects (Ahmadian et al., 2013) . PGC-1b is believed to be a prevalent PPARg co-activator in the osteoclastogenic process. Its expression is enhanced during osteoclast differentiation, and its deletion arrests formation of the bone-resorptive cell, in vitro, particularly when induced by ROSI (Ishii et al., 2009; Wei et al., 2010) . Because ASXL2 exerts its osteoclastogenic effects in conjunction with PPARg, we asked whether PGC-1b participates in the process. Mirroring the effects of PPARg deletion, absence of ASXL2 completely obviates PGC-1b expression both basally and when induced by ROSI.
Dysfunctional mitochondrial biogenesis is central to the pathogenesis of insulin-resistant DM (Petersen et al., 2003; Vianna et al., 2006) . This mitochondrial dysfunction is mediated by PGC-1a and its closest homolog, PGC-1b. Whereas overexpression of either increases mitochondrial respiration in cultured cells, they are non-compensatory, as deletion of either promotes a robust phenotype and selectively alters gene expression (Lin et al., 2004; Sonoda et al., 2007) . This event is of particular significance in osteoclasts that, because of profound energy consumption, are extremely rich in mitochondria whose generation requires PGC-1b. In fact, absence of PGC-1b arrests the boneresorptive function of mature osteoclasts, in vivo (Ishii et al., 2009 ). However, the relative importance of PGC-1b and its induction of mitochondrial biogenesis to osteoclast formation were unknown.
Similar to PGC-1b, absence of ASXL2 diminishes basal and stimulated mitochondrial biogenesis. However, unlike c-Fos or NFATc1, which rescue the ASXL2À/À osteoclast phenotype, reconstitution with PGC-1b has no effect on differentiation of the mutant cells. These observations are consistent with the fact that, whereas PGC-1bÀ/À osteoclast number is diminished, in vitro, it is normal, in vivo, but function of the cell is disturbed (Ishii et al., 2009) . In a physiological context, therefore, PGC-1b and by association mitochondrial biogenesis likely exert their effects by enabling resorptive activity and not by promoting osteoclast differentiation.
Arrest of differentiation-induced expression of RANK and its effector osteoclastogenic signals provided a candidate mechanism for failure to optimally form the bone-resorbing cells in the absence of ASXL2. Thus, it was surprising that normalization of RANK does not increase c-Fos, which when transduced into ASXL2À/À BMMs, rescues their osteoclast-poor phenotype. PGC-1b transduction, which promotes mitochondrial biogenesis, also fails to induce c-Fos or osteoclast formation in ASXL2À/À cells. Thus, regardless of agonist, osteoclastogenesis requires c-Fos, which in turn requires ASXL2. We propose that, in contradistinction to PGC-1b, which via mitochondrial biogenesis directly facilitates bone resorption, the primary osteoclastic effect of c-Fos, which does not enhance PGC-1b expression or mitochondrial biogenesis, is maturation, with increased bone degradation being a secondary consequence. Thus, ASXL2 regulates osteoclast formation and function, respectively, by two distinct signaling pathways.
The role of ASXL2 in skeletal, glucose, and lipid homeostasis establishes that this particular gene regulates all three systems. On the other hand, the products of ASXL2-mediated regulation, such as osteoclastogenesis and insulin sensitivity, appear to be independent events that do not mutually impact each other. Thus, murine ASXL2 insufficiency predisposes to lipodystrophy, insulin resistance, and attendant skeletal dysfunction, raising the possibility that ASXL2 may affect similar endpoints in people.
EXPERIMENTAL PROCEDURES
Detailed information is available in the Supplemental Experimental Procedures.
Mice ASXL2+/À mice (C57BL background and S129 background) were described previously (Baskind et al., 2009) . To generate ASXL2À/À mice, C57BL ASXL2+/À mice were mated with S129 ASXL2+/À mice; F1 offspring were used for all experiments. Mice were housed in the animal care unit of Washington University School of Medicine, where they were maintained according to guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care. All animal experimentation was approved by the Animal Studies Committee of Washington University School of Medicine.
Statistics
Statistical significance was determined using Student's t test. Data are expressed as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 in all experiments.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, five figures, and one table and can be found with this article online at http:// dx.doi.org/10.1016/j.celrep.2015.05.019.
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